1352-Menin Inhibition Targets Pathogenic Megakaryopoiesis

This paper details research into menin inhibition as a novel therapeutic strategy for myeloproliferative neoplasms (MPNs), a group of blood cancers characterized by excessive cell production and bone marrow fibrosis. Researchers discovered that the menin-KMT2A interaction is essential for the survival and maturation of megakaryocyte progenitors, which are the primary drivers of disease progression in conditions like myelofibrosis. Utilizing the inhibitor revumenib, the study demonstrates a significant reduction in pathogenic megakaryocytes and a successful reversal of bone marrow scarring in various animal models. This treatment selectively targets malignant cells by downregulating key genes such as MEF2C and MEIS1 without disrupting normal JAK/STAT signaling. Furthermore, the findings suggest that combining revumenib with existing treatments like ruxolitinib creates a synergistic effect that further normalizes blood counts and reduces spleen size. Ultimately, the sources provide a strong preclinical rationale for using menin inhibitors to address unmet medical needs in patients with MPNs.References:Wen J, Cotton A, Mehmood R, et al. Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms[J]. Cancer Cell, 2026.前往小宇宙评论区与主播互动